Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, 2-Period, Fixed-sequence, Phase 1 Study in Healthy Volunteers to Evaluate the Effect of Itraconazole, a Potent CYP3A Inhibitor, on the Pharmacokinetics of IW-1973

Trial Profile

An Open-label, 2-Period, Fixed-sequence, Phase 1 Study in Healthy Volunteers to Evaluate the Effect of Itraconazole, a Potent CYP3A Inhibitor, on the Pharmacokinetics of IW-1973

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2018

At a glance

  • Drugs Praliciguat (Primary) ; Itraconazole
  • Indications Cardiovascular disorders; Diabetic nephropathies; Heart failure; Hypertension in diabetes; Pulmonary arterial hypertension
  • Focus Pharmacokinetics
  • Sponsors Ironwood Pharmaceuticals
  • Most Recent Events

    • 19 Jul 2018 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2018 Planned End Date changed from 2 Jul 2018 to 9 Jul 2018.
    • 07 Jun 2018 Planned primary completion date changed from 2 Jul 2018 to 9 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top